Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluating the Effect of Mirtazapine on Anxiety in Parkinson's Disease Patients
Sponsor: Leila Dargahi. PharmD PhD
Summary
This study is a single-center, parallel and double-blind study in Movement Disorders Clinic of Shohadaye Tajrish Hospital. Patients, researchers (physicians, outcome assessors) and data analysts are blinded. After assessing the inclusion and exclusion criteria's, patients who assigned the informed consent form, are randomly divided into control and treatment groups.Patients in treatment or placebo groups respectively receive mirtazapine (15 mg) or placebo, once a day for 12 weeks. Primary (anxiety) and secondary (depression, fatigue, sleep disorders, and quality of life) outcomes are evaluated at baseline, and after 4 and 12 weeks of treatments.
Official title: Evaluating the Effect of Mirtazapine on Anxiety in Parkinson's Disease Patients; a Randomized Double-blinded Placebo-controlled Clinical Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2022-06-01
Completion Date
2026-06-30
Last Updated
2025-05-21
Healthy Volunteers
No
Conditions
Interventions
Mirtazapine 15 MG
Mirtazapine (15 mg), once a day for 12 weeks
Placebo
Placebo, once a day, for 12 weeks
Locations (1)
Shahid Beheshti University of Medical Sciences, Shohada-e-Tajrish Hospital
Tehran, Iran